Ex-Vivo Trial of En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

  • STATUS
    Recruiting
  • End date
    Sep 30, 2025
  • participants needed
    25
  • sponsor
    National Cancer Institute (NCI)
Updated on 24 October 2022
radical cystectomy
cancer
x-rays
bladder cancer
invasive bladder cancer
transurethral resection
bladder tumor
transurethral bladder excision

Summary

Background

Bladder cancer is the sixth most common cancer in the United States. The way that doctors remove tumors in bladder surgeries may leave some cancer . Also, many people have their tumors return or progress after surgery. Researchers want to test a modified device. It might tell doctors more about bladder tumors.

Objective

To see if using a modified standard device with bladder surgery can provide better information about tumors in bladder specimens.

Eligibility

People ages 18 and older who need to have their bladder removed at the NIH.

Design

Participants will be screened with:

Medical and prior surgical history

Review of existing MRI, x-ray, or CT scans

Review of existing specimens and reports

Pregnancy test for women of childbearing age

CT or MRI: Participants will lie in a machine. The machine will take pictures of their body.

Participants will have bladder surgery. This will occur in the same way as if they did not take part in this study. A member of the research team will cut the removed bladder using the modified device. This will most likely be done on a separate back table in the operating room. The bladder and samples after cutting will be sent out for review. The will occur just as it would if the participants were not in this study. The only difference is the way that the specimen is prepared for review.

Participants follow-up care will occur per standard of care. Or it will occur as part of any other study in which they might also be enrolled.

Description

Background
  • Bladder cancer is the sixth most common cancer in the United States, disproportionately affecting more men than women.
  • The gold standard for the surgical treatment and diagnosis of non-muscle invasive bladder cancer is transurethral resection of bladder tumors (TURBT).
  • TURBT requires the fragmentation of bladder tumors and piecemeal removal of these tumors.
  • TURBT leads to loss of histopathologic information - including tumor orientation, size, and margin status - which may compromise outcomes and risk tumor seeding within the bladder.
  • Given these multiple problems with TURBT we are testing some modifications to the current resectoscope device and the effect of these modifications on the quality of TURBT specimens produced.
  • The redesigned resectoscope device will be tested ex-vivo on cystectomy specimens to avoid risks to patient safety.
    Objectives

The primary objective of this study is to determine if resectoscope device modification can provide improved pathologic standards for the TURBT procedure. An improvement in any of the parameters outlined below will constitute a device improvement in the current resectoscope:

  • Presence of three tissue layers within the tumor specimens containing bladder mucosa, lamina propria, and portions of the muscularis.
  • Information regarding tumor margin, assessed as the ability to ascertain if tumor is present at the margin of the resection.
    Eligibility
  • Medical condition requiring surgical removal of the bladder
  • Men and women, age >= 18 years
    Design
  • Preclinical tissue acquisition trial, ex vivo, proof-of-concept.
  • Following cystectomy, a modified resectoscope/redesigned resectoscope will be used to resect areas of tumor from the cystectomy specimens. These resected tumors will be sent with the cystectomy specimen for histopathology to assess the size of resection, depth of resection, and ability to ascertain tumor orientation.
  • The remainder of the cystectomy specimens will undergo traditional histopathology. Histopathologic information from both specimens will be included in the final histopathologic diagnosis to ensure accurate oncology staging.
  • This study will allow for about 2 years of accrual and the accrual ceiling will be set at 25 subjects.

Details
Condition Bladder Cancer
Treatment modified resectoscope, TURBT
Clinical Study IdentifierNCT04235764
SponsorNational Cancer Institute (NCI)
Last Modified on24 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients requiring surgical removal of the bladder at the NIH Clinical Center
NOTE: Reasons for need for surgical removal of bladder include cancer or benign condition
for which a surgeon determined surgical removal of the bladder is recommended. Patient's
with invasive bladder cancer requiring cystectomy are eligible for enrollment. Bladder
cancer remains the most common reason for cystectomy. Patients with clinical advanced
disease and having other treatments/or participating in other trials remain eligible for
enrollment in this study
Men and women
Age greater than or less than 18 years
Ability of subject to understand and the willingness to sign a written informed
Deemed clinically appropriate for the planned surgical procedure
consent document
Subjects will be asked to co-enroll in 15-C-0087, "Care of the Urothelial Cancer
Patient and Prospective Collection of Biospecimens from Healthy Volunteers and
Urothelial Cancer Patients." NOTE: Most participants are expected to already be
enrolled in 15-C-0087 prior to entry in this study

Exclusion Criteria

Cystectomy during pregnancy would subject the fetus to significant risk of miscarriage or
premature labor. For this reason, pregnant women are ineligible for this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note